Response Depth and Consolidative Therapy in Advanced Renal Cell Carcinoma

Dr. Serzan discusses the clinical significance of response depth in advanced renal cell carcinoma (RCC), highlighting evidence from the CLEAR trial that greater tumor reduction, particularly complete responses, is associated with more favorable long-term outcomes. He explains how the depth and durability of response can also influence subsequent management, including consideration of treatment de-escalation in selected patients with complete responses and management of residual disease in those with ongoing tumor burden. The conversation then turns to consolidative approaches, including cytoreductive nephrectomy and other local therapies, for carefully selected patients with metastatic clear cell RCC who demonstrate sustained systemic disease control. Dr. Serzan emphasizes the importance of multidisciplinary evaluation and notes that decisions regarding surgery should consider the extent and stability of disease outside the kidney and the patient's response over time. Dr. Voss reinforces a cautious approach when considering surgery, particularly when the optimal timing remains uncertain, highlighting the need to balance potential benefits against procedural risks in patients receiving systemic therapy for advanced RCC.